Baseline cardiopulmonary exercise testing characteristics of the participants.
| Variables | NCTHF (n=894) | CTHF (n=75) | P values* | P values† |
| Peak VO2, mL/min/kg | 15.3±6.3 | 16.0±5.8 | 0.33 | 0.40 |
| % Predicted peak VO2 | 61.2±20.2 | 62.4±20.2 | 0.62 | 0.44 |
| VE/VCO2 slope | 33.0±8.8 | 32.4±6.9 | 0.55 | 0.43 |
| Haemodynamic | ||||
| Resting HR, bpm | 72±14 | 79±16 | <0.001 | <0.001 |
| Peak HR, bpm | 122±28 | 138±31 | <0.001 | 0.003 |
| Chronotropic index | 0.53±0.28 | 0.64±0.30 | 0.001 | 0.024 |
| HR recovery at 1 min, bpm | 20±15 | 22±17 | 0.25 | 0.11 |
| Resting SBP, mm Hg | 117±20 | 112±19 | 0.020 | 0.64 |
| Peak SBP, mm Hg | 141±29 | 134±29 | 0.049 | 0.29 |
| Resting DBP, mm Hg | 74±11 | 71±13 | 0.036 | 0.46 |
| Peak DBP, mm Hg | 75±12 | 73±13 | 0.18 | 0.46 |
| Peak RER | 1.19±0.13 | 1.23±0.14 | 0.006 | 0.048 |
Data are presented as mean±SD.
*Unadjusted.
†Adjusted for age, sex and body mass index.
CTHF, cancer therapy-induced heart failure; DBP, diastolic blood pressure; HR, heart rate; NCTHF, non-cancer therapy-induced heart failure; RER, respiratory exchange ratio; SBP, systolic blood pressure.